Skip to Content
by Leigh MacMillan | Posted on Thursday, Nov. 21, 2013 — 9:30 AM
Synovial sarcoma – an aggressive soft-tissue cancer most commonly diagnosed in children and young adults – has a low survival rate and no effective systemic treatments. The oncogene SYT-SSX has been associated with synovial sarcoma, but how it drives tumorigenesis is unclear.
Josiane Eid, M.D., adjunct assistant professor of Cancer Biology, and colleagues investigated a possible link between SYT-SSX and Wnt/beta-catenin signaling – a developmental signaling pathway that is deregulated in many cancers.
Using synovial sarcoma cell cultures, sarcoma tumor xenografts and an SYT-SSX2 transgenic mouse model in which tumors develop that are similar to human synovial sarcoma tumors, they demonstrated that SYT-SSX2 activates Wnt/beta-catenin signaling. They showed that this signaling is necessary for synovial sarcoma growth and that inhibitors of Wnt signaling arrest synovial sarcoma tumor growth.
The findings, reported in the November issue of Cancer Discovery, reveal the critical role of Wnt/beta-catenin signaling in synovial sarcoma pathogenesis, and suggest that inhibitors of this pathway may be effective therapeutic agents for difficult-to-treat sarcomas.
Send suggestions for articles to highlight in Aliquots and any other feedback about the column to email@example.com
Leigh MacMillan, (615) 322-4747
Health and Medicine, Reporter, Research alex's lemonade stand foundation, Aliquots, cancer biology, Cancer Discovery, cell and developmental biology, Department of Veterans Affairs, Ethan Lee, Fiona Yull, Josiane Eid, NCI, NIGMS, NIH, Reporter Nov 22 2013, sarcoma, targeted cancer therapy, Vanderbilt Ingram Cancer Center, Wnt signaling
There are lots of ways to keep up with Vanderbilt. Choose your preferred method: